Praxis Precision Medicines, Inc. (PRAX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Boston, MA, 미국. 현재 CEO는 Marcio Silva De'Souza.
PRAX 을(를) 보유 IPO 날짜 2020-10-16, 116 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $7.26B.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders caused by neuronal imbalance. The company's lead candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor modulator in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor in Phase IIa development for essential tremor. Praxis is also advancing PRAX-562 for severe pediatric epilepsy and adult headache disorders, along with antisense oligonucleotide programs PRAX-222 and KCNT1 targeting genetic forms of epilepsy. Founded in 2015 and headquartered in Boston, Massachusetts, the company has established partnerships with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, and The Florey Institute to support its clinical pipeline.
